US › Healthcare

Fate Therapeutics Inc (FATE)

US · Healthcare · Biotechnology

$2.52+3.28%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$2.1M

Revenue YoY

+9.2%

Net profit

$-30.2M

EPS

$-0.25

EPS estimate

$-0.28

Net margin

-1,448.6%

EPS came in at -0.25 against a street estimate of -0.28 — a beat of 10.7%.

Key statistics

Market cap

$281.6M

Forward P/E

0.0

P/B

1.82

Book value

$1.31

EPS (TTM)

$-1.06

52-week high

$3.23

52-week low

$0.94

50-day MA

$2.61

200-day MA

$1.76

Beta

2.55

Analyst view

Analysts rate Fate Therapeutics Inc a buy (6 buy, 6 hold, 0 sell out of 12) with an average price target of $5.74.

Shareholding

Insiders

1.06%

Institutions

68.96%

Largest institutional holders

Fund	Stake
Redmile Group, LLC	10.74%
BlackRock Inc	8.40%
Vanguard Capital Management, LLC	3.50%
Vanguard Portfolio Management, LLC	3.45%
Acadian Asset Management LLC	3.44%
Two Sigma Investments LLC	2.89%
Johnson & Johnson	2.82%
AQR Capital Management LLC	2.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fate Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.